The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 24, 2021
Filed:
Jan. 24, 2020
Applicant:
The General Hospital Corporation, Boston, MA (US);
Inventors:
J. Keith Joung, Winchester, MA (US);
Shengdar Tsai, Charlestown, MA (US);
Assignee:
The General Hospital Corporation, Boston, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/90 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); C12N 15/01 (2006.01); C07K 14/005 (2006.01); C07K 14/195 (2006.01); C12N 9/02 (2006.01); C12N 9/10 (2006.01); C12N 9/16 (2006.01); C12N 9/96 (2006.01); C12N 15/85 (2006.01); C12N 9/22 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
C12N 15/907 (2013.01); C07K 14/005 (2013.01); C07K 14/195 (2013.01); C12N 9/0071 (2013.01); C12N 9/1007 (2013.01); C12N 9/16 (2013.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/01 (2013.01); C12N 15/102 (2013.01); C12N 15/1031 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); C12N 15/85 (2013.01); C12Y 301/21004 (2013.01); C07K 2319/00 (2013.01); C07K 2319/01 (2013.01); C07K 2319/80 (2013.01); C12N 2310/20 (2017.05); C12N 2710/00033 (2013.01); C12N 2770/00033 (2013.01); C12N 2800/80 (2013.01); C12Y 114/11 (2013.01); C12Y 201/01 (2013.01); C12Y 301/00 (2013.01);
Abstract
Many studies have shown that CRISPR-Cas nucleases can tolerate up to five mismatches and still cleave; it is hard to predict the effects of any given single or combination of mismatches on activity. Taken together, these nucleases can show significant off-target effects but it can be challenging to predict these sites. Described herein are methods for increasing the specificity of genome editing using the CRISPR/Cas system, e.g., using RNA-guided FokI Nucleases (RFNs), e.g., FokI-Cas9 or FokI-dCas9-based fusion proteins.